562 related articles for article (PubMed ID: 1711565)
1. Phospholipid-anchored and transmembrane versions of either decay-accelerating factor or membrane cofactor protein show equal efficiency in protection from complement-mediated cell damage.
Lublin DM; Coyne KE
J Exp Med; 1991 Jul; 174(1):35-44. PubMed ID: 1711565
[TBL] [Abstract][Full Text] [Related]
2. Cooperation between decay-accelerating factor and membrane cofactor protein in protecting cells from autologous complement attack.
Brodbeck WG; Mold C; Atkinson JP; Medof ME
J Immunol; 2000 Oct; 165(7):3999-4006. PubMed ID: 11034410
[TBL] [Abstract][Full Text] [Related]
3. Expression of a hybrid complement regulatory protein, membrane cofactor protein decay accelerating factor on Chinese hamster ovary. Comparison of its regulatory effect with those of decay accelerating factor and membrane cofactor protein.
Iwata K; Seya T; Ariga H; Nagasawa S
J Immunol; 1994 Apr; 152(7):3436-44. PubMed ID: 7511647
[TBL] [Abstract][Full Text] [Related]
4. Alternative exon usage in the 3' region of a single gene generates glycosylphosphatidylinositol-anchored and transmembrane forms of rat decay-accelerating factor.
Miwa T; Okada N; Okada H
Immunogenetics; 2000 Feb; 51(2):129-37. PubMed ID: 10663575
[TBL] [Abstract][Full Text] [Related]
5. Signal transduction through decay-accelerating factor. Interaction of glycosyl-phosphatidylinositol anchor and protein tyrosine kinases p56lck and p59fyn 1.
Shenoy-Scaria AM; Kwong J; Fujita T; Olszowy MW; Shaw AS; Lublin DM
J Immunol; 1992 Dec; 149(11):3535-41. PubMed ID: 1385527
[TBL] [Abstract][Full Text] [Related]
6. Mouse complement regulatory protein Crry/p65 uses the specific mechanisms of both human decay-accelerating factor and membrane cofactor protein.
Kim YU; Kinoshita T; Molina H; Hourcade D; Seya T; Wagner LM; Holers VM
J Exp Med; 1995 Jan; 181(1):151-9. PubMed ID: 7528766
[TBL] [Abstract][Full Text] [Related]
7. Characterisation of the complement-regulatory proteins decay-accelerating factor (DAF, CD55) and membrane cofactor protein (MCP, CD46) on a human colonic adenocarcinoma cell line.
Bjørge L; Jensen TS; Matre R
Cancer Immunol Immunother; 1996 Mar; 42(3):185-92. PubMed ID: 8640847
[TBL] [Abstract][Full Text] [Related]
8. Characterization of a glycosyl-phosphatidylinositol anchor-deficient subline of Raji cells. An analysis of the functional importance of complement inhibitors on the Raji cell line.
Harris CL; Morgan BP
Immunology; 1995 Oct; 86(2):311-8. PubMed ID: 7490134
[TBL] [Abstract][Full Text] [Related]
9. Protection of xenogeneic cells from human complement-mediated lysis by the expression of human DAF, CD59 and MCP.
Huang J; Gou D; Zhen C; Jiang D; Mao X; Li W; Chen S; Cai C
FEMS Immunol Med Microbiol; 2001 Oct; 31(3):203-9. PubMed ID: 11720816
[TBL] [Abstract][Full Text] [Related]
10. Decay-accelerating factor (CD55), a glycosylphosphatidylinositol-anchored complement regulatory protein, is a receptor for several echoviruses.
Bergelson JM; Chan M; Solomon KR; St John NF; Lin H; Finberg RW
Proc Natl Acad Sci U S A; 1994 Jun; 91(13):6245-8. PubMed ID: 7517044
[TBL] [Abstract][Full Text] [Related]
11. The CD46 transmembrane domain is required for efficient formation of measles-virus-mediated syncytium.
Seya T; Kurita M; Iwata K; Yanagi Y; Tanaka K; Shida K; Hatanaka M; Matsumoto M; Jun S; Hirano A; Ueda S; Nagasawa S
Biochem J; 1997 Feb; 322 ( Pt 1)(Pt 1):135-44. PubMed ID: 9078253
[TBL] [Abstract][Full Text] [Related]
12. Complement-mediated tumor cell damage induced by antibodies against membrane cofactor protein (MCP, CD46).
Seya T; Hara T; Matsumoto M; Sugita Y; Akedo H
J Exp Med; 1990 Dec; 172(6):1673-80. PubMed ID: 2258699
[TBL] [Abstract][Full Text] [Related]
13. Characterization of mouse DAF on transfectant cells using monoclonal antibodies which recognize different epitopes.
Ohta R; Imai M; Fukuoka Y; Miwa T; Okada N; Okada H
Microbiol Immunol; 1999; 43(11):1045-56. PubMed ID: 10609614
[TBL] [Abstract][Full Text] [Related]
14. Relative roles of decay-accelerating factor, membrane cofactor protein, and CD59 in the protection of human endothelial cells against complement-mediated lysis.
Brooimans RA; van Wieringen PA; van Es LA; Daha MR
Eur J Immunol; 1992 Dec; 22(12):3135-40. PubMed ID: 1280224
[TBL] [Abstract][Full Text] [Related]
15. Mapping of epitopes, glycosylation sites, and complement regulatory domains in human decay accelerating factor.
Coyne KE; Hall SE; Thompson S; Arce MA; Kinoshita T; Fujita T; Anstee DJ; Rosse W; Lublin DM
J Immunol; 1992 Nov; 149(9):2906-13. PubMed ID: 1383332
[TBL] [Abstract][Full Text] [Related]
16. Protection of human nasal respiratory epithelium from complement-mediated lysis by cell-membrane regulators of complement activation.
Varsano S; Frolkis I; Rashkovsky L; Ophir D; Fishelson Z
Am J Respir Cell Mol Biol; 1996 Dec; 15(6):731-7. PubMed ID: 8969267
[TBL] [Abstract][Full Text] [Related]
17. Identification of complement regulatory domains in human factor H.
Gordon DL; Kaufman RM; Blackmore TK; Kwong J; Lublin DM
J Immunol; 1995 Jul; 155(1):348-56. PubMed ID: 7541419
[TBL] [Abstract][Full Text] [Related]
18. Mechanisms by which the surface expression of the glycosyl-phosphatidylinositol-anchored complement regulatory proteins decay-accelerating factor (CD55) and CD59 is lost in human leukaemia cell lines.
Hatanaka M; Seya T; Matsumoto M; Hara T; Nonaka M; Inoue N; Takeda J; Shimizu A
Biochem J; 1996 Mar; 314 ( Pt 3)(Pt 3):969-76. PubMed ID: 8615796
[TBL] [Abstract][Full Text] [Related]
19. Characterization of a Trypanosoma cruzi C3 binding protein with functional and genetic similarities to the human complement regulatory protein, decay-accelerating factor.
Norris KA; Bradt B; Cooper NR; So M
J Immunol; 1991 Oct; 147(7):2240-7. PubMed ID: 1717552
[TBL] [Abstract][Full Text] [Related]
20. Decay-accelerating factor and membrane cofactor protein.
Lublin DM; Atkinson JP
Curr Top Microbiol Immunol; 1990; 153():123-45. PubMed ID: 1688754
[No Abstract] [Full Text] [Related]
[Next] [New Search]
